Neogenomics IncChange company Symbol lookupSelect an option...NEO Neogenomics IncCHEK Check Cap LtdSTOK Stoke Therapeutics IncDUOT Duos Technologies Group IncBCLI Brainstorm Cell Therapeutics IncEEX Emerald Holding IncJPM-L JPMorgan Chase & CoSBFM Sunshine Biopharma IncSEKEY Seiko Epson CorpPXMD PaxMedica IncGo
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: Clinical Services, and Advanced Diagnostics. The Clinical Services segment provides various clinical-testing services related to oncology diagnostics, community-based oncology and pathology sales, patient engagement, and clinical decision support. The Clinical Services segment also offers Trapelo, a decision-making informatics tool, to help health care professionals navigate the rapidly evolving field of precision medicine. The Advanced Diagnostics segment includes pharma services, informatics, research and development, and minimal residual disease, liquid biopsy and therapy selection business development. Additional offerings within the Advanced Diagnostics portfolio include Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data.
|
|
|
|
| |
Company Profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: Clinical Services, and Advanced Diagnostics. The Clinical Services segment provides various clinical-testing services related to oncology diagnostics, community-based oncology and pathology sales, patient engagement, and clinical decision support. The Clinical Services segment also offers Trapelo, a decision-making informatics tool, to help health care professionals navigate the rapidly evolving field of precision medicine. The Advanced Diagnostics segment includes pharma services, informatics, research and development, and minimal residual disease, liquid biopsy and therapy selection business development. Additional offerings within the Advanced Diagnostics portfolio include Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 2.81x
- Price/Book (MRQ)
- 1.62x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in millions.
Company Officers
- Lynn A. TetraultChmn.
- Christopher M. SmithCEO
- Jeffrey Scott ShermanCFO
- Melody HarrisCorp.Exec.
- Vishal SikriCorp.Exec.
Address
- 9490 Neogenomics Way
- Fort Myers, FL 33912
- Phone: (239) 768-0600
- Fax: (775) 329-0852
- https://neogenomics.com/
Insider Trading
No insider trading activity.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.